Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816979 · ClinicalTrials.gov registry record · NA
Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT06816979 is a NA study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT06816979, a NA study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I trial assesses the use of lumbar punctures to detect whether there is circulating tumor deoxyribonucleic acid (ctDNA) in the fluid that surrounds the brain and spinal cord (cerebrospinal fluid) in patients with stage III and IV non-small cell lung cancer (NSCLC). Patients with stage III and IV NSCLC are at risk of having their cancer spread from where it first started to the brain (metastatic). Because of this, more effective prognostic tools are necessary to determine which stage III and IV NSCLC patients are more likely to develop brain metastases. Cerebrospinal fluid (CSF) could be a reliable source of ctDNA to confirm and predict the presence of brain metastases in these patients. Assessing cell free DNA shed from tumor cells could be a sensitive and minimally invasive way to detect or characterize metastatic tumors in the central nervous system (CNS). Lumbar puncture is procedure in which a thin needle called a spinal needle is put into the lower part of the spinal column to collect CSF. Lumbar punctures for the collection of CSF may help doctors detect or measure changes in cell types, genes, and proteins of circulating tumor cells related to lung cancer that will help determine the presence of brain metastases which could become a standard of care screening tool utilized in the follow-up of patients diagnosed with stage II or IV NSCLC.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Lumbar Puncture
- DEVICE Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06816979
The ClinicalTrials.gov registry entry for NCT06816979 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT06816979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06816979 about?
NCT06816979 is a clinical study titled "Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer". This phase I trial assesses the use of lumbar punctures to detect whether there is circulating tumor deoxyribonucleic acid (ctDNA) in the fluid that surrounds the brain and spinal cord (cerebrospinal fluid) in patients with stage III and IV non-small cell lung cancer (NSCLC). Patients with stage III...
What is the current status of trial NCT06816979?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-09-15. Estimated completion is 2028-01-31.
What interventions are being tested in trial NCT06816979?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Lumbar Puncture (PROCEDURE), Magnetic Resonance Imaging (DEVICE).
Who is sponsoring clinical trial NCT06816979?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.